- Tags: ARVO
Research
Rosacea may double risk for DR progression
Patients with rosacea and early-stage DR had more than twice the risk of progressing to proliferative disease—and a higher need for retinal intervention over 5 years.
Research
Oral health may be key in protecting vision, new findings suggest
Periodontal disease associated with higher risk of developing eye conditions, adding to growing evidence that oral health may influence overall health far beyond the mouth.
Research
Study suggests ocular history may raise risk for recurrent shingles
Recurrent herpes zoster ophthalmicus clustered in the eight weeks immediately following shingles vaccination, with nearly all cases tied to pre-existing ocular involvement.
Research
Neuvasq highlights novel antibody approach for restoring blood-retina barrier in wet AMD and DME
Preclinical data of NVQ401 and NVQ501 demonstrate improvements in BRB integrity and function in vascular retinopathy models.
Pipeline
Preliminary data evaluates Astellas's RPE cell therapy for advanced GA
Presented at ARVO 2026, early 26- and 52-week safety phase 1b data from highlights notable visual gains in patients receiving ASP7317.
Research
Oculis's global DME consensus study identifies critical gaps in care
Expert panel highlights disease management while emphasizing the importance of early intervention and non-invasive treatment options based on BCVA outcomes.
Research
Real-world TED data finds disease advances beyond acute phase
Real-world study demonstrates heterogeneous disease progression in TED, challenging the traditional self-limited paradigm.
Events
ARVO 2026 signals a turning point for retina innovations
Highlights from this year’s research in vision and ophthalmology meeting covered genetics, gene editing, AI, advanced imaging, and more.
Pipeline
New SightGlass 24-month data shows DOT lenses significantly slow pediatric myopia progression
Unveiled at ARVO 2026, DOT lenses saved more than 1 D of myopic progression on average after 2 years among 6-to-10-year-old wearers.
Products
ARVO 2026: Heidelberg debuts new ophthalmic imaging and data management tech
Medtech company premiers still-investigational imaging platform with OCT, a fully digitally surgical microscope, and additions to the HEYEX 2 platform.
Research
Could oral contraceptives lead to retinal thinning?
Duration of oral contraceptive use mediated the impact on retinal morphology.
Research
New data supports Hoya's DIMS lenses for myopic prevention among preschool-aged pediatrics
Presented at ARVO, updated findings among the younger pre-myopics confirmed a protective effect of the patented and embedded technology on refractive status.
Products
Zeiss debuts new research data platform for integrated workflows
Company’s cloud-based solution uses AI technology to integrate accessible clinical and research data into clinicians’ daily routines.
Pipeline
Favorable safety data supports Alkeus' oral gildeuretinol for dry AMD
Presented during ARVO 2025, the modified form of Vitamin A demonstrated a slower decline in vision-related quality of life among patients diagnosed with GA secondary to AMD.Products
Heidelberg showcases fully digital surgical visualization platform
The SeeLuma features an ergonomically-friendly design, 3D technology, and a new intraoperative OCT module, among other add-ons, for surgeons.
Research
Could insulin eye drops provide corneal healing?
Researchers share new findings on the effectiveness of insulin therapy for neurotrophic keratitis.
Research
How accurate are consumer reviews of OTC eye care products?
Cross-sectional study analyzes 210 of the top products sold on Amazon and store retailers.
Research
Could ranibizumab be more effective for ROP than laser therapy?
RAINBOW extension study evaluates 5-year outcomes for ranibizumab 0.2 mg and 0.1 mg vs YAG laser therapy in improving visual acuity.
Research
New data on Eylea HD supports prolonged dosing for wet AMD
Presented at ARVO, 96-week extending dosing supports reduced need for frequent injections.
Research